Professor Bruce Johnson, MD, received his medical degree from the University of Minnesota in Minneapolis, MN, in 1979, after which he completed his postgraduate training at the University of Chicago in Chicago, IL, where he completed his residency, and the National Cancer Institute, where he completed a fellowship. Prof. Johnson is certified in both internal medicine and medical oncology.
Prof. Johnson currently leads the Dana-Farber/Harvard Cancer Center Lung Cancer Program and is the Chief Clinical Research Officer at the Dana-Farber Cancer Institute in Boston, MA. He is also a Professor of Medicine at Harvard Medical School in Boston, MA, and has previously served as head of the Lung Cancer Biology Section of the National Cancer Institute. He also served as the President of the American Society of Clinical Oncology (ASCO) between 2017 and 2018.
Speaking on genomic changes in thoracic malignancies
Prof. Johnson’s primary research focus is on the impact of genomic changes on the targeted treatment of thoracic malignancies, with a particular focus on lung cancer. He is involved in translational research testing novel therapeutic agents with specific genomic changes, including identification of the link between mutations of EGFR and repost to the EGFR tyrosine kinase inhibitors, gefitinib and erlotinib.